Literature DB >> 9198202

The treatment of deep vein thrombosis and pulmonary embolism.

F Turkstra1, M M Koopman, H R Büller.   

Abstract

Deep vein thrombosis and pulmonary embolism can be considered as one clinical entity, termed venous thromboembolism, because of their comparable pathogenesis, treatment and prognosis. In this clinical spectrum of venous thromboembolism a gradient in severity of the disease can be recognized. Therapeutic strategies should be adapted to the extent of the thrombotic disease, varying from surgical or thrombolytic therapy in life-threatening disease to a watchful waiting diagnostic follow-up approach in minimal disease. In patients with established venous thromboembolism (low molecular weight) (LMWH), heparin should be initiated. An overview will be given of the safety and efficacy of the different therapeutic modalities such as thrombectomy, thrombolytic therapy, a watchful waiting diagnostic approach and unfractionated heparin. Furthermore, clinical studies comparing LMWH with unfractionated heparin in the initial treatment of venous thromboembolism will be reviewed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9198202

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

Review 1.  Massive pulmonary embolus with hemodynamic compromise: therapeutic options.

Authors:  Derek G Lohan; Carmel G Cronin; Conor P Meehan; Stephen T Kee; Michael D Dake; Ian R Davidson; Gerard J O'Sullivan
Journal:  Emerg Radiol       Date:  2006-11-18

Review 2.  Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.

Authors:  Susan M Cheer; Christopher J Dunn; Rachel Foster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Epidemiology of recurrent venous thrombosis.

Authors:  D D Ribeiro; W M Lijfering; S M Barreto; F R Rosendaal; S M Rezende
Journal:  Braz J Med Biol Res       Date:  2011-12-23       Impact factor: 2.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.